Bayer BristolMyers Squibb and Ono Collaborate to Investigate the Combination of Stivarga and Opdivo in Patients with Metastatic Colorectal Cancer

Bayer, Bristol-Myers Squibb and Ono Collaborate to Investigate the Combination of Stivarga and Opdivo in Patients with Metastatic Colorectal Cancer

10:52 EDT 18 Jul 2019 | Speciality Pharma Journal

WHIPPANY, N.J. & PRINCETON, N.J. & OSAKA, Japan–(BUSINESS WIRE)–Bayer, Bristol-Myers Squibb Company (NYSE: BMY) and Ono Pharmaceutical Co., Ltd. (“Ono”) announced today the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer’s kinase inhibitor Stivarga® (regorafenib) and Bristol-Myers Squibb’s / Ono’s anti-PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab) in patients with micro-satellite stable metastatic …

More From BioPortfolio on "Bayer, Bristol-Myers Squibb and Ono Collaborate to Investigate the Combination of Stivarga and Opdivo in Patients with Metastatic Colorectal Cancer"